Tevogen bio reports nasdaq listing compliance as ceo reaffirms his commitment in bridging the information gap about the company

Warren, n.j., oct. 29, 2024 (globe newswire) -- tevogen bio (“tevogen” or “tevogen bio holdings inc.”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t cell therapeutics to treat infectious disease and cancers, announced today that on october 28, 2024, it received written notice from the listing qualifications staff of the nasdaq stock market llc (“nasdaq”) stating that the company has regained compliance with the minimum bid price requirement (the “minimum bid price requirement”), as set forth in nasdaq listing rule 5550(a)(2) for continued listing on the nasdaq global market.
GPS Ratings Summary
GPS Quant Ranking